SCHEMBL2118659

SCHEMBL2118659

CCCCCCCCCCCCCCC(=O)C(=O)N[C@H](C(=O)NCC(=O)OC)C(C)C

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 6/20 0.63
PLA2G5 P39877 3/20 0.63
BIRC2 Q13490 1/20 0.44
FURIN P09958 2/20 0.42
RECQL P46063 1/20 0.41
PLA2G4A P47712 1/20 0.41
PRSS1 P07477 1/20 0.41
CES2 O00748 3/20 0.40
CES1 P23141 3/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
FAAH O00519 1/20 0.40
MAPK1 P28482 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 1/20 0.39
POLA1 P09884 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
EPHX2 P34913 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119427 0.90 PLA2G2A (0.58) PLA2G2APLA2G5BIRC2FURINPLA2G4A
SCHEMBL2120792 0.88 PLA2G2A (0.69) PLA2G2APLA2G5PLA2G4ACES2CES1
SCHEMBL2120784 0.88 PLA2G2A (0.69) PLA2G2APLA2G5PLA2G4ACES2CES1
SCHEMBL2119442 0.80 BIRC2 (0.49) PLA2G2APLA2G5BIRC2FURINRECQL
SCHEMBL2119438 0.80 BIRC2 (0.49) PLA2G2APLA2G5BIRC2FURINRECQL
SCHEMBL2119446 0.80 BIRC2 (0.49) PLA2G2APLA2G5BIRC2FURINRECQL
SCHEMBL1873320 0.79 PLA2G2A (0.71) PLA2G2APLA2G5BIRC2RECQLPLA2G4A
SCHEMBL30798618 0.78 PLA2G2A (1.00) PLA2G2APLA2G5PLA2G4ACES2CES1
SCHEMBL29948915 0.78 PLA2G2A (1.00) PLA2G2APLA2G5PLA2G4ACES2CES1
SCHEMBL2118667 0.78 PLA2G2A (0.76) PLA2G2APLA2G5PLA2G4ACES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580852-B2 2-oxamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudopeptides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-11-12 US disclosed
US-20120095096-A1 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-04-19 US disclosed
WO-2010123832-A2 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095096-A1 2-OXAMIDE INHIBITORS OF PHOSPHOLIPASE A2 ACTIVITY AND CELLULAR ARACHIDONATE RELEASE BASED ON DIPEPTIDES AND PSEUDOPEPTIDES PLA2G2E, PLA2G4A, PLAA PLA2G2A 6/4885PLA2G5 16/4885BIRC2 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.